fashion -WSS

fashion

author：explore 2025-09-30 17:44:14 - browse：96

Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. — A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.

This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： WHO calls for emergency meeting on new China virus, as cases spread

WSS

How to fix the rural physician shortage in the U.S.

Why getting cancer drugs just got harder for rural patients

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Sanofi seeks simpler, safer CRISPR sickle cell cure

Doctors find melanoma drugs effective against rare brain cancer

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

hotspot

fashion

hotspot

Activists slam private health insurers over coverage restrictions

Listen: Wegovy in the brain & pivotal Alzheimer's data

Affirmative action in medical school literally saved lives

FDA approves RSV monoclonal antibody for infants, toddlers

Walensky prepares to leave CDC — and Congress — behind

STAT Virtual Event: The State of Biosimilars: What to Watch

Duchenne breakthrough therapy leaves behind pioneering families

Startup Neumora takes a novel depression drug to Phase 3

Wildfire smoke exposes gaps in outdoor worker protections

Medical device lobby: We're tired of waiting on Medicare coverage

focus

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

FogPharma raises $145 million in rare Series E round

Key House panel plots a new health care package

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Key House panel plots a new health care package

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

focus

focus

hotspot

entertainment